The Washington Post

IBM’s Watson, New York Genome Center partner on brain cancer treatment

Watson researchers work inside IB Thomas J. Watson Research Center, the headquarters of the company's research, in Yorktown Heights, New York, U.S., on Tuesday, Feb. 11, 2014. IBM’s Watson group is partnering with the New York Genome Center to devise software that could help physicians suggest more personalized treatment to patients. (Scott Eells/Bloomberg)

Could IBM’s Watson soon be a cancer specialist?

The Watson Group — IBM’s new business unit dedicated to the cognitive computing system — is partnering with the New York Genome Center, a biomedical research nonprofit, to analyze the genomes of cancer patients, the company announced Wednesday.

The two will collaborate on a computing prototype that could suggest treatment options for patients with glioblastoma, an aggressive brain cancer. Watson would analyze an individual patient’s genome, and compare it to large volumes of data from other patients, as well as medical literature, to recommend experimental treatments.

Since it created the Watson Group in January, IBM has been rapidly marketing the software; for instance, it recently announced it would be using Watson in parts of Africa to solve problems related to education and healthcare. This is the first time Watson has been applied to genomic research.

Ultimately, physicians and patients would make treatment decisions, but consider Watson’s input, Ajay Royyuru, director of research at IBM, said in an interview. “In the situation of actually giving care to reach patients, it’s safe to say there is never going to be a solution that replaces the expertise of physicians.”

Watson learns as it goes; as new information about the outcome of these patients’ treatments is fed back into the system, it can refine its recommendations, according to IBM.

As the cost of acquiring genomic information is rapidly decreasing, using that information to influence treatment is becoming easier, Royyuru explained.

“Genetics requires the compassion of the physician to be combined with the power of the technology, and there’s no better place to do that in patients who are desperately ill,” said Robert Darnell, president, chief executive and scientific director at the New York Genome Center. “[For glioblastoma] patients that are going to die within a year — the ethical imperative is to try to help in a way that minimizes risk.”



Success! Check your inbox for details. You might also like:

Please enter a valid email address

See all newsletters

Show Comments
Most Read



Success! Check your inbox for details.

See all newsletters

Your Three. Videos curated for you.
Play Videos
Deaf banjo player teaches thousands
Perks of private flying
Drawing as an act of defiance
Play Videos
Husband finds love, loss in baseball
Bao: The signature dish of San Francisco
From foster homes to the working world
Play Videos
How soccer is helping Philadelphia men kick the streets
Here's why you hate the sound of your own voice
The woman behind the Nats’ presidents ‘Star Wars’ makeover
Play Videos
How hackers can control your car from miles away
How to avoid harmful chemicals in school supplies
How much can one woman eat?

To keep reading, please enter your email address.

You’ll also receive from The Washington Post:
  • A free 6-week digital subscription
  • Our daily newsletter in your inbox

Please enter a valid email address

I have read and agree to the Terms of Service and Privacy Policy.

Please indicate agreement.

Thank you.

Check your inbox. We’ve sent an email explaining how to set up an account and activate your free digital subscription.